These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 26604805)

  • 1. Delamanid expanded access novel treatment of drug resistant tuberculosis.
    Rustomjee R; Zumla A
    Infect Drug Resist; 2015; 8():359-66. PubMed ID: 26604805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
    Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.
    Kwon YS; Jeong BH; Koh WJ
    Expert Opin Pharmacother; 2015 Feb; 16(2):253-61. PubMed ID: 25327169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis.
    Sotgiu G; Pontali E; Centis R; D'Ambrosio L; Migliori GB
    Expert Rev Anti Infect Ther; 2015 Mar; 13(3):305-15. PubMed ID: 25645397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.
    Khan U; Huerga H; Khan AJ; Mitnick CD; Hewison C; Varaine F; Bastard M; Rich M; Franke MF; Atwood S; Khan PY; Seung KJ
    BMC Infect Dis; 2019 Aug; 19(1):733. PubMed ID: 31429722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis.
    Blair HA; Scott LJ
    Drugs; 2015 Jan; 75(1):91-100. PubMed ID: 25404020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-Resistant
    Khoshnood S; Taki E; Sadeghifard N; Kaviar VH; Haddadi MH; Farshadzadeh Z; Kouhsari E; Goudarzi M; Heidary M
    Front Microbiol; 2021; 12():717045. PubMed ID: 34690963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delamanid Kills Dormant Mycobacteria
    Chen X; Hashizume H; Tomishige T; Nakamura I; Matsuba M; Fujiwara M; Kitamoto R; Hanaki E; Ohba Y; Matsumoto M
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of delamanid in the treatment of drug-resistant tuberculosis.
    Lewis JM; Sloan DJ
    Ther Clin Risk Manag; 2015; 11():779-91. PubMed ID: 25999726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delamanid for multidrug-resistant pulmonary tuberculosis.
    Gler MT; Skripconoka V; Sanchez-Garavito E; Xiao H; Cabrera-Rivero JL; Vargas-Vasquez DE; Gao M; Awad M; Park SK; Shim TS; Suh GY; Danilovits M; Ogata H; Kurve A; Chang J; Suzuki K; Tupasi T; Koh WJ; Seaworth B; Geiter LJ; Wells CD
    N Engl J Med; 2012 Jun; 366(23):2151-60. PubMed ID: 22670901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Status of Delamanid in the Management of MDR Tuberculosis.
    Karekar SR; Marathe PA
    J Assoc Physicians India; 2018 Jul; 66(7):72-75. PubMed ID: 31325268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New anti-tuberculosis drugs and regimens: 2015 update.
    D'Ambrosio L; Centis R; Sotgiu G; Pontali E; Spanevello A; Migliori GB
    ERJ Open Res; 2015 May; 1(1):. PubMed ID: 27730131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Implications of New Drugs and Regimens for the Treatment of Drug-resistant Tuberculosis.
    Kwon YS
    Chonnam Med J; 2017 May; 53(2):103-109. PubMed ID: 28584788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delamanid for the treatment of pulmonary multidrug-resistant tuberculosis.
    Thakare R; Soni I; Dasgupta A; Chopra S
    Drugs Today (Barc); 2015 Feb; 51(2):117-23. PubMed ID: 25756067
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.